A review of the safety of sodium‐glucose co‐transporter‐2 inhibitors

Documenti analoghi

• Superior benefits of sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors for diabetic kidney disease: A cohort study
  di: Hsiao‐Ling Chen, et al.
  Pubblicazione: (2024)
• Slowing the progression of diabetic and non‐diabetic kidney disease: A summary of the current evidence base for sodium‐glucose co‐transporter‐2 inhibitors
  di: Viktor Rotbain Curovic, et al.
  Pubblicazione: (2024)
• A meta‐analysis of randomized controlled studies examining the effects of sodium‐glucose co‐transporter‐2 inhibitors on peripheral artery disease and risk of amputations
  di: Li Geng, et al.
  Pubblicazione: (2024)
• Clinical characteristics and outcomes of diabetes‐related ketoacidosis ( DKA ) in sodium‐glucose co‐transporter‐2 inhibitor ( SGLT2i ) users with type 2 diabetes
  di: Angelica Sharma, et al.
  Pubblicazione: (2025)
• Effects of sodium‐glucose cotransporter‐2 inhibitors in myocardial infarction patients: A systematic review and meta‐analysis
  di: Qiufeng Jia, et al.
  Pubblicazione: (2024)